Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 279 recruiting now early-phase tilt #6 of 28,707 conditions

Cancer: early-phase trial registry

279 of 621 indexed Cancer trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #6 of 28,707 conditions by registered trial count.

621 US clinical trials · 279 currently recruiting · #6 of 28,707 conditions by registered trial count

Cancer: 621 US clinical trials tracked, 279 recruiting.

Cancer is the subject of 621 registered US clinical trials on ClinicalTrials.gov, 279 of them currently open to new participants. 31 are in Phase 3-4 (later-stage) and 164 in Phase 1-2 (earlier-stage). The most active sponsor is M.D. Anderson Cancer Center, running 31 of these trials.

Enrollment posture brief

Registry condition cancer

OPEN 279 | RECR 45% | LATE 31 | EARLY 164 | RANK #6 | SPON 31

Nearest open-share peer: Duchenne Muscular Dystrophy (45% recruiting · 49 trials)

Cancer (this)45%Prostate Cancer36.7%Depression35.7%Hypertension32.2%HIV Infections9.1%
Open-enrollment share among volume-matched conditions near Cancer

Cancer lists 279 open slots (45% of 621 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Cancer on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Cancer is recruiting above its size-band peers.

    279 of 621 indexed trials (44.9%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. Sponsorship of Cancer trials is spread across many organizations.

    M.D. Anderson Cancer Center accounts for 31 of 621 trials (5%). 270 distinct sponsors appear on at least one study for this condition label.

  3. Typical Cancer enrolment sits around 108 participants.

    Median target enrolment is 108 among the 616 trials that report a genuine target (sentinel values excluded). 287 of those (46.6%) plan for fewer than 100 participants.

  4. Cancer research is mostly interventional.

    462 interventional and 159 observational studies make up this index (74.4% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 1116Phase 248Phase 327Phase 44

Open and recent trials

621 total, page 13 of 13

COMPLETED NA 12 participants

Physical and Emotional Benefits of Group Dance Intervention for Breast Cancer Survivors

University of the Sciences in Philadelphia

NCT02793076

COMPLETED Phase 2 12 participants

Trial of Thalidomide, a- Interferon +/- Octreotide in Patients With Unresectable Hepatocellular Carcinoma

University of New Mexi

NCT00250796

COMPLETED Phase 1 11 participants

Evaluating the Use of RFT5-dgA to Deplete Alloreactive Cells Prior to Haploidentical Stem Cell Transplantation

Baylor College of Medicine

NCT00586547

COMPLETED NA 11 participants

Usefulness of Acupuncture in Cancer Pain and Quality of Life

Southern California University of Health Sciences

NCT00401063

COMPLETED 10 participants

The Biodistribution of 1-[2 Deoxy-2, -18 Fluroarabinfuranosyl]Cytosine [18FAC] in Healthy Subjects and Patients With Cancer, Autoimmune/Inflammatory Diseases

Jonsson Comprehensive Cancer Center

NCT01180907

COMPLETED Phase 1 10 participants

A Phase I Trial Using Combination Irinotecan and Thalidomide for Recurrent CNS Tumors

University of New Mexi

NCT00251797

COMPLETED Phase 1 10 participants

Intranasal (NAS) Ketamine for Cancer Pain

Emory University

NCT03146806

COMPLETED 10 participants

Catheter Resistance Monitoring to Predict Catheter-Associated Adverse Events in Children and Adolescents

St. Jude Children's Research Hospital

NCT01737554

COMPLETED NA 9 participants

Modex, a Cloud-based, Centralized Health Economic Model Marketplace to Reduce Costs and Enhance Equity in Cancer

Arnold Consultancy & Technology

NCT07361458

COMPLETED Phase 1 7 participants

TCR-engineered T Cells in Solid Tumors (ACTengine IMA201-101)

Immatics US

NCT03247309

COMPLETED Phase 2 7 participants

Tadalafil and Pembrolizumab in Recurrent or Metastatic Head and Neck Cancer

University of California, San Diego

NCT03993353

COMPLETED NA 7 participants

Williams LifeSkills - Cancer Caregiver Intervention

Duke University

NCT03174626

COMPLETED Phase 1 6 participants

Study of Kinetics, Dosimetry & Safety of [18F]F-AraG, a Positron Emission Tomography Imaging Tracer in Healthy Humans

CellSight Technologies

NCT02323893

COMPLETED Phase 1 6 participants

Determination of the Absolute Bioavailability of GSK2118436 Following a Single Oral Dose Co-Administered With an Intravenous Radiolabelled Microtracer of GSK2118436 in Subjects With BRAF Mutant Solid Tumors

GlaxoSmithKline

NCT01340833

COMPLETED Early Phase 1 4 participants

Study of Oral Ketamine Versus Placebo for Treating Depression in Patients Undergoing Treatment for Cancer

Scott A. Irwin, MD, PhD

NCT02836288

COMPLETED Phase 1 3 participants

Exercise Therapy in Cancer Patients Who Are Recovering From COVID-19

Memorial Sloan Kettering Cancer Center

NCT04824443

COMPLETED NA

Acupuncture in Treating Mucositis-Related Pain Caused by Chemotherapy in Patients Undergoing Stem Cell Transplantation

National Cancer Institute (NCI)

NCT00060021

COMPLETED Phase 3

Efficacy and Safety of Sublingual Fentanyl Tablets in Treatment of Breakthrough Pain in Cancer Patients.

Kyowa Kirin Co.

NCT00262678

COMPLETED Phase 3

Ribavirin With or Without Monoclonal Antibody Therapy in Treating Patients Who Develop RSV Pneumonia Following Peripheral Stem Cell Transplantation

Fred Hutchinson Cancer Center

NCT00014391

COMPLETED Phase 1

BCX-1777 in Treating Patients With Refractory Cancer

BioCryst Pharmaceuticals

NCT00073944

COMPLETED Phase 3

Caspofungin Acetate Compared With Amphotericin B Liposomal in Treating Patients With Persistent Fever and Neutropenia Following Cancer Treatment

Memorial Sloan Kettering Cancer Center

NCT00008359

← Previous Page 13 of 13

Phase Distribution

PhaseTrial count
Phase 1 116
Phase 2 48
Phase 3 27
Phase 4 4

Named interventions

Most-linked intervention names on Cancer records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Usual Care Other
6 trials
Carboplatin Drug
6 trials
Bevacizumab Drug
6 trials
Pembrolizumab Drug
6 trials
Radiation therapy Radiation
4 trials
Usual Care Behavioral
4 trials
Atezolizumab Drug
4 trials
Placebo Drug
4 trials

US sites by state

Facility locations filed on Cancer trials. A trial with sites in several states counts in each.

California 142 trials
Texas 106 trials
Florida 90 trials
New York 88 trials
Pennsylvania 68 trials
North Carolina 63 trials
Massachusetts 59 trials
Tennessee 50 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Cancer page

621 registered trials, 279 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Cancer condition card totals 621 registered trials; most-linked intervention Usual Care; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.